Indivior (LON:INDV) Shares Down 15.7% - What's Next?

Indivior PLC (LON:INDV) experienced a sharp decline in its stock price, dropping 15.7% on Thursday. The shares fell to a low of GBX 548.71 ($6.95) before closing at GBX 732 ($9.28). The trading volume reached approximately 1,888,371 shares, a significant increase of 166% compared to the average daily volume of 709,477 shares. Previously, Indivior's stock had closed at GBX 868 ($11.00).

Stock Performance Insights

The decline in share price has raised questions among investors regarding the next steps. As of now, Indivior commands a market capitalization of £1.14 billion. The company's financial metrics reveal a price-to-earnings (P/E) ratio of -606.93 and a price-to-earnings growth (PEG) ratio of -5.57. The stock's beta stands at 0.19, indicating low volatility. Additionally, the firm's 50-day moving average is at GBX 924.76, while the 200-day moving average is GBX 852.88. Current financial ratios include a current ratio of 0.83, a quick ratio of 1.52, and an unusual debt-to-equity ratio of -170.06.

Recent Analyst Sentiments

In the wake of the stock's downturn, there have been some mixed sentiments from analysts. Recently, Jefferies Financial Group reiterated a "buy" rating for Indivior's shares, setting a target price of GBX 1,800 ($22.81). This suggests that some analysts maintain a positive outlook despite the recent drop in price.

About Indivior

Indivior PLC is engaged in the development, manufacture, and sale of buprenorphine-based prescription medications aimed at treating opioid dependence and related disorders. The company operates not only in the United States and the United Kingdom but also on an international scale. Indivior focuses on creating solutions for substance use disorders, serious mental health conditions, and opioid overdose incidents.

Investor Considerations

As investors review their options, it may be essential to reflect on the broader context of Indivior's operations and the healthcare sector. MarketBeat has identified several stocks considered better buys than Indivior, despite its current "buy" rating from analysts. Notably, top-rated research analysts believe that there are five stocks that may offer more promising investment opportunities.

For those contemplating whether to invest $1,000 in Indivior at this time, it is crucial to weigh all factors and possibly explore other alternatives as identified by market analysts.

Indivior, Stock, Shares